Analysis of immunoglobulin heavy variable chain rearrangement in chronic lymphocytic leukemia patients among Chornobyl clean-up workers
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.14839Ключові слова:
chronic lymphocytic leukemia, immunoglobulin variable heavy chain (IGHV) rearrangement, ionizing radiationАнотація
Summary. Background: A number of epidemiological studies have shown an elevated radiation-associated risk for chronic lymphocytic leukemia (CLL). The aim of the paper was to analyze immunoglobulin heavy variable chain (IGHV) rearrangement and IGHV usage in CLL cases associated with ionizing radiation (IR) exposure. Materials and Methods: Samples of 76 clean-up workers of Chornobyl Nuclear Power Plant accident of 1986 (the main group) and 194 non-exposed patients (the control group) were analyzed. Two groups of CLL patients were comparable by gender (all patients were male), age, and place of residence (rural or urban). Results: Some features of IR-associated CLL cases as compared to CLL cases in patients without history of IR exposure were revealed. Among unmutated IGHV sequences, IGHV1 genes were less commonly used (29.4% vs 48.6%; p = 0.018), while the frequency of IGHD6 genes was higher (23.5% vs 10%; p = 0.029). The unmutated IGHV sequences did not use IGHD3-16 gene (0% vs 7.9%, p = 0.038). Mutated IGHV sequences were less frequently expressed IGHV3 genes (44% vs 68.5%; p = 0.037) due low representation of IGHV3-21 (4% vs 11.1%) and IGHV3-23 (0% vs 11.1%) genes; did not use IGHD3-22 gene (0% vs 18.5%, p = 0.025); and have signs of positive selection in the HCDR regions (Σ = 0.5029 ± 0.155 vs –0.0539 ± 0.14; p = 0.013). Conclusions: The revealed differences in IGHV gene usage and B-cell receptor structure in the main and the control groups of CLL patients indirectly indicate a change in the spectrum of antigens associated with CLL under IR exposure. The possible antigenic drivers associated with CLL associated with IR exposure are discussed.
Посилання
Romanenko A, Finch S, Hatch M, et al. The Ukrainian-American study of leukemia and related disorders among Chornobyl cleanup workers from Ukraine: III. Radiation risks. Radiat Res 2008; 170: 711–20.
Zablotska LB, Bazyka D, Lubin JH, et al. Radiation and the risk of chronic lymphocytic and other leukemias among Chornobyl clean-up workers. Environ Health Perspect 2013; 121: 59–65.
Bazyka D, Gudzenko N, Dyagil I, et al. Cancers after Chornobyl: from epidemiology to molecular quantification. Cancers (Basel) 2019; 11: 1291.
Gluzman DF, Sklyarenko LM, Nadgornaya VA, Zavelevich MP. Mature B-cell neoplasms in Chernobyl clean-up workers of 1986-1987: summary of cytomorphological and immunocytochemical study in 25 years after Chernobyl accident. Exp Oncol 2011; 33: 47–51.
Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–47.
Agathangelidis A, Vardi A, Baliakas P, Stamatopoulos K. Stereotyped B-cell receptors in chronic lymphocytic leukemia. Leuk Lymphoma 2014; 55: 2252–61.
Jain N, O’Brien S. Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Rev 2016; 30: 233–44.
Kipps TJ, Zhang S. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol 2014; 9: 103–18.
Ten Hacken E, Gounari M, Ghia P, Burger JA. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia 2019; 33: 287–98.
Bazyka D, Prysyazhnyuk A, Gudzenko N, et al. Epidemiology of late health effects in Ukrainian Chornobyl cleanup workers. Health Phys 2018; 115: 161–9.
Bhattacharya S, Asaithamby A. Ionizing radiation and heart risks. Semin Cell Dev Biol 2016; 58: 14–25.
Deas SD, Huprikar N, Skabelund A. Radiation exposure and lung disease in today’s nuclear world. Curr Opin Pulm Med 2017; 23: 167–72.
Chumak A, Thevenon C, Gulaya N, et al. Monohydroxylated fatty acid content in peripheral blood mononuclear cells and immune status of people at long times after the Chernobyl accident. Radiat Res 2001; 156: 476–87.
Chumak A.A, Abramenko IV, Bilous NI, et al. Persistent infections and their relationship with selected oncologic and non-tumor pathologies. J Immunotoxicol 2010; 7: 279–88.
Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–34.
Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, eds. CLL recent progress and future directions, vol. 59. UCLA Symposia on Molecular and Cellular Biology. New York: Alan R. Liss, 1987: 253.
Binet JL, Auguier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariant survival analysis. Cancer. 1981; 48: 198–205.
Abramenko I, Bilous N, Chumak A, et al. Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident — with focus on immunoglobulin heavy chain gene analysis. Leuk Res 2008; 32: 535–45.
Hamblin TJ, Davis Z, Garddiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–54.
Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–7.
Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008; 111: 1524–33.
Yaari G, Uduman M, Kleinstein SH. Quantifying selection in high-throughput Immunoglobulin sequencing data sets. Nucleic Acids Res 2012; 40: 134.
Uduman M, Yaari G, Hershberg U, et al. Detecting selection in immunoglobulin sequences. Nucleic Acids Res 2011; 39: 499–504.
Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies. Blood 2012; 119: 4467–75.
Silverman GJ, Goodyear CS. A model B-cell superantigen and the immunobiology of B lymphocytes. Clin Immunol 2002; 102: 117–34.
Silverman GJ, Goodyear CS. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 2006; 6: 465–75.
Catera R, Silverman GJ, Hatzi K, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008; 14: 665–74.
Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008; 111: 3838–48.
Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119: 1335–49.
Que X, Widhopf2nd GF, Amir S, et al. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde–acetaldehyde adduct, an immunodominant oxidation-specific epitope. PLoS One 2013; 8: e65203.
Hamblin TJ, Oscier DG. Chronic lymphocytic leukaemia: the nature of the leukaemic cell. Blood Rev 1997; 11: 119–28.
Underbayev C, Kasar S, Ruezinsky W, et al. Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia. Oncotarget 2016; 7: 60986–99.
Hayakawa K, Formica AM, Colombo MJ, et al. B cells generated by B-1 development can progress to chronic lymphocytic leukemia. Ann N Y Acad Sci 2015; 1362: 250–5.
Hillion S, Arleevskaya MI, Blanco P, et al. The innate part of the adaptive immune system. Clin Rev Allergy Immunol 2019; https://doi.org/10.1007/s12016-019-08740-1. [Epub ahead of print]
Bomben R. Dal-Bo M, Benedetti D, et al. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Clin Cancer Res 2010; 16: 620–8.
Kolibab K, Smithson SL, Rabquer B, et al. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect Immun 2005; 73: 7465–76.
Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014; 48: 41–51. https://doi.org/10.1093/jncimonographs/lgu001.
Steininger C, Widhopf2nd GF, Ghia EM, et al. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood 2012; 199: 2293–2301. https://doi.org/10.1182/blood-2011-08-374058.
Kostareli E, Hadzidimitriou A, Stavroyianni N, et al. Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Leukemia 2009; 23: 919–24.
Steininger C, Rassenti LZ, Vanura K, et al. Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest 2009; 39: 497–506.
Wang C, Liu Y, Xu LT, et al. Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires. J Immunol 2014; 192: 603–11.
Jiang N, He J, Weinstein JA, et al. Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med 2013; 5: 171ra19.
Laserson U, Vigneault F, Gadala-Maria D, et al. High-resolution antibody dynamics of vaccine-induced immune responses. Proc Natl Acad Sci U S A 2014; 111: 4928–33.
Galson JD, Trück J, Fowler A, et al. Analysis of B cell repertoire dynamics following hepatitis B vaccination in humans, and enrichment of vaccine-specific antibody sequences. EBioMedicine 2015; 12: 2070–9. https://doi.org/10.1016/j.ebiom.2015.11.034.
Galson JD, Trück J, Clutterbuck EA, et al. B-cell repertoire dynamics after sequential hepatitis B vaccination and evidence for cross-reactive B-cell activation. Genome Med 2016; 8: 68.
Davydov AN, Obraztsova AS, Lebedin MY, et al. Comparative analysis of B-cell receptor repertoires induced by live yellow fever vaccine in young and middle-age donors. Front Immunol 2018; 9: 2309.
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2023 Експериментальна онкологія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
